Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024)
Zenas BioPharma (ZBIO) posted quarterly Preferred Stock Liabilities of $199.5 million for Q2 2024, up 3.23% quarter-over-quarter from $193.3 million in Q1 2024.
Zenas BioPharma (ZBIO) Preferred Stock Liabilities (2023 - 2024) Analysis & Trends
Zenas BioPharma's Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $199.5 million for Q2 2024.
- In Q2 2024, Preferred Stock Liabilities changed N/A year-over-year to $199.5 million; the TTM figure through Jun 2024 stood at $199.5 million (changed N/A YoY), while the FY2023 annual figure was $250.1 million, changed N/A from the prior year.
- Preferred Stock Liabilities for Q2 2024 stood at $199.5 million, up from $193.3 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $250.1 million in Q4 2023, with the low at $193.3 million in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 199.53 Mn |
| Mar 31, 2024 | 193.29 Mn |
| Dec 31, 2023 | 250.09 Mn |
| Sep 30, 2023 | 193.29 Mn |